Donald Trump & Merck Group

Donald Trump: Signed the executive order, driving the policy change. His actions face widespread criticism from medical and public health organizations, potentially affecting his political standing and public trust in health agencies.

Merck Group: As a major MMR manufacturer, it faces potential regulatory and market changes. It stated no scientific evidence supports splitting the vaccine, and it may face pressure to develop separate shots.

Donald Trump: Trump's executive order and unsubstantiated claim about the MMR vaccine's lethality have sparked widespread criticism from health experts and fact-checkers, potentially undermining public trust in vaccines and his administration's health policies.

Merck Group: Merck, the sole U.S. manufacturer of the MMR vaccine, stated it cannot produce separate shots for at least 10 years. The executive order could create regulatory and market uncertainty, though current sales are unaffected.

Donald Trump: His administration's funding cuts triggered the global decline, central to the event.

Merck Group: Announced plans to allow generic production of alimatravir, potentially expanding market access.

Donald Trump: As President, Trump's administration has pushed back on mRNA technology, but the trial results may influence policy and public perception.

Merck Group: Merck co-developed the vaccine and provided Pembrolizumab, the combination partner. Its shares rose about 10-12%, and the success helps Merck prepare for Pembrolizumab's patent expiration by expanding its cancer portfolio.